Mammakarzinom

Titel
Studie
Jahr

Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018.

Oncol Res Treat 41 (suppl 4)(P916).

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

IMPROVE
2018

Palbociclib in combination with letrozole as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welslau, M., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P919).

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

INGE-B
2018

An observational study to evaluate the effectiveness of OnLife® in improving chemotherapy-induced peripheral neuropathy in patients with colon or breast cancer after end of adjuvant therapy: Design of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P945).

Indikation: KolorektalkarzinomMammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

STEFANO
2018

Does progression influence the quality of life? – Data from patients with advanced breast cancer from the MaLife-Project.

Marschner N., Söling, U., Scholz, H., Azeh, I., Chiabudini, M., Kruggel, L., Jänicke, M., 2018.

Oncol Res Treat 41 (suppl.4) (V493)

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2018

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., the TMK-Group (Tumour Registry Breast Cancer), 2018.

Breast Cancer Res Treat 167(2), 567–578. doi:10.1007/s10549-017-4534-8

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2018

Final Effectiveness and Safety Results of NABUCCO – Real-World Data from a Non-Interventional, Prospective, Multi-Center Study in 697 Patients with Metastatic Breast Cancer Treated with Nab-Paclitaxel.

Marschner, N., C. Salat, U. Söling, R. Hansen, S. Grebhardt, J. Harde, A. Nusch, and K. Potthoff.

Epub ahead of print: Clinical Breast Cancer 0, no. 0 (15 July 2018). https://doi.org/10.1016/j.clbc.2018.07.010.

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Clinical Breast Cancer

NABUCCO
2018

MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., Sohn, J.H., Lee, K.S., Sarker, S.-J., Coetzee, C., Mousa, K., Castan, J.C., 2018.

Cancer Res 78(4 Supplement), GS2-07-GS2-07. doi:10.1158/1538-7445.SABCS17-GS2-07

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

MANTA
2018

705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Mammakarzinom; Veranstaltung: DKK; Journal:

NABUCCO
2018

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel, S., Steffens, C.-C., Meyer, D., Tesch, H., Kruggel, L., Frank, M., Jänicke, M., Marschner, M. 2017.

Breast Cancer, 4 December 2017, 1–9. https://doi.org/10.1007/s12282-017-0823-7.

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer

TMK
2017

How much does fatigue, pain and treatment time interfere with daily life of patients with breast cancer? – Data from the MaLife-Project.

Marschner, N., Scholz, H., Behringer, J., Frank, M., Kruggel, L., Jänicke, M., for the TMK Registry Group, 2017.

Oncol Res Treat 40(suppl 3)(V796), 226. doi:10.1159/000479566

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2017

Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventinal study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhart, S., Harde, J., Marschner, N., 2017.

Ann Oncol 28 (Supplement 5)(293P), 97. doi:10.1093/annonc/mdx365

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

NABUCCO
2017

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017.

BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1

Indikation: Mammakarzinom; Veranstaltung: -; Journal: BMC Cancer

PASO
2017

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., Cancer), 2017.

Breast Cancer Res Treat 1–12. doi:10.1007/s10549-017-4534-8

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2017

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study.

Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017.

The Breast 34, 122–130. doi:http://dx.doi.org/10.1016/j.breast.2017.05.014

Indikation: Mammakarzinom; Veranstaltung: -; Journal: The Breast

TMK
2017

Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO.

Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017.

J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555

Indikation: Mammakarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

NABUCCO
2017

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.

Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2017

Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study.

Schröder, J., Fietz, T., Köhler, A., Petersen, V., Tesch, H., Spring, L., Fleitz, A., Jänicke, M., Marschner, N., 2017.

Eur J Cancer 79, 139–148. doi:10.1016/j.ejca.2017.03.031

Indikation: Mammakarzinom; Veranstaltung: -; Journal: European Journal of Cancer

TMK
2017

MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Ferreira, M., Dubey, S., Zaiss, M., Harper-Wynne, C., Makris, A., Brown, V., Kristeleit, H., Patel, G., Perelló, A., Jones, A., Mithal, N., Ruiz, I., Kümmel, S., Brunt, A.M., Guerra, J.A., Cao, M.G., Saura, C., Mousa, K., Sarker, S.-J., Coetzee, C., Swann, R., Cortes, J., 2016.

Cancer Res 76(4 Supplement), OT1-03-12-OT1-03-12. doi:10.1158/1538-7445.SABCS15-OT1-03-12

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

MANTA
2016

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.

Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S., 2016.

Breast Cancer Res Treat 156, 97–107. doi:10.1007/s10549-016-3727-x

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

CARIN
2016

Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, Grebhardt, S., Marschner, N., 2016.

Ann Oncol (2016) 27 (suppl_6): 236P. doi:10.1093/annonc/mdw365.15

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

NABUCCO
2016

Wechselnde Symptombelastung – gleichbleibende Lebensqualität? – Longitudinale Daten des MaLife-Projekts zu Patientinnen mit metastasiertem Mammakarzinom unter Monochemo- bzw. Hormontherapie.

Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2016.

Senologie – Zeitschrift für Mammadiagnostik und -therapie 02, P074. doi:10.1055/s-0036-1583404

Indikation: Mammakarzinom; Veranstaltung: Senologie Kongress; Journal: Senologie

TMK
2016

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Kurbacher, C., Fietz, T., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016.

Ann Oncol (2016) 27 (suppl_6): 1457P. doi:10.1093/annonc/mdw390.25

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

NADIR
2016

Patient-reported outcomes of 905 patients with breast cancer two years after start of curative systemic treatment.

Marschner, N., Trarbach, T., Dörfel, S., Meyer, D., Müller-Hagen, S., Zaiss, M., Boller, E., Kruggel, L., 2016.

Oncol Res Treat 39 (suppl 5)(V385), 116. doi:10.1159/000449050

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2016

Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Marschner, N., Potthoff, K., Salat, C., Söling, U., Hansen, R., Grebhardt, S., Harde, Nusch, A., 2016.

Oncol Res Treat 39 (suppl3)(P598), 183. doi:10.1159/000449050

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NABUCCO
2016

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Kurbacher, C.M., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016.

Oncol Res Treat 39 (suppl3)(P952), 293. doi:10.1159/000449050

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NADIR
2016

No impact of increasing symptoms on quality of life? Longitudinal data from the German MALIFE-Project on patients receiving monochemo- and endocrine treatment for advanced breast cancer – results from the TMK registry group.

Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015.

The Breast 24 (suppl3) (OR51), 39. doi:10.1016/S0960-9776(15)30063-1

Indikation: Mammakarzinom; Veranstaltung: ABC3; Journal: The Breast

TMK
2015

No impact of increasing symptom burden on quality of life? – Longitudinal data from the German MaLife-Project on patients receiving monochemo- and endocrine treatment for metastatic breast cancer.

Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015.

Oncol Res Treat 38 (suppl 5)(V670), 202. doi:10.1159/00043907

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2015

Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: subgroup analysis of the non-interventional study NADIR.

Kurbacher, C., Fietz, T., Salat, C., Zaiss, M., Gazawi, N., Steffens, C.-C., Egert, M., Graffunder, G., Papke, J., Weißenborn, G., Brückner, U., Illmer, T., Jungberg, P., Lorenz, A., Weide, R., Klare, P., Tesch, H., Oskay-Oezcelik, G., Teichmann, B., Harde, J., Scheuerlein, R., 2015.

Oncol Res Treat 38 (suppl.5)(P255), 77–78. doi:10.1159/000439070

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NADIR
2015

Osteoprotektive Behandlung von Patientinnen mit ossär metastasiertem Mammakarzinom – Daten zur Behandlungsrealität aus dem Tumorregister Mammakarzinom.

Köhler, A., Tesch, H., Nusch, A., Fietz, T., Kruggel, L., Spring, L., Jänicke, M., Marschner, N., 2015.

Senologie – Zeitschrift für Mammadiagnostik und -therapie 12, A77 (02). doi:10.1055/s-0035-1550517

Indikation: Mammakarzinom; Veranstaltung: Senologie Kongress; Journal: Senologie

TMK
2015

Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Keitel, S., Hesse, T., 2015.

Cancer Res 76 (4 Suppl)(P4-14-08). doi:10.1158/1538-7445.SABCS15-P4-14-08

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

Herceptin-NIS
2015

Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy.

Thill, M., Ziegler-Löhr, K., Wagner, H., Helling-Giese, G., Greinemann, J., Schmalhofer, O., Reichert, D., 2015.

Cancer Res 75 (9 Suppl)(P5-19–11). doi:10.1158/1538-7445.SABCS14-P5-19-11

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

HELENA
2014

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study.

Müller, V., Fuxius, S., Steffens, C.-C., Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Hurst, U., Hahn, L.-J., Soeling, U., Wohlfarth, T., Zaiss, M., 2014.

Oncol Res Treat 37, 6–6. doi:10.1159/000369487

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Oncology Research and Treatment

Xeloda-NIS
2014

Final efficacy and safety analysis of the CARIN phase III trial: Cap and Bev with or without Vin in 1st line metastatic breast cancer (MBC).

Welt, A., Marschner, N., Lerchenmüller, C., Decker, T., Salat, C., Busies, S., Hegewisch-Becker, S., 2014.

Ann Oncol, ESMO (Madrid) 25, iv119 (359PD). doi:10.1093/annonc/mdu329.9

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

CARIN
2014

Wirksamkeit erneuter Anti-HER2-Therapie mit Herceptin® in der klinischen Routine bei erstem Rezidiv und/oder erster Metastasierung des HER2-positiven Mammakarzinoms – 4. Interimanalyse der nichtinterventionellen Studie (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014.

Senologie 11(02), A50(P027). doi:10.1055/s-0034-1375409

Indikation: Mammakarzinom; Veranstaltung: Senologie Kongress; Journal: Senologie

Herceptin-NIS
2014

Efficacy of anti-HER2 ReTherapy with Herceptin® at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine – 4th interim analysis of the non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014.

Ann Oncol 25(suppl4), iv131 (400P). doi:10.1093/annonc/mdu329.49

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

Herceptin-NIS
2014

Chemotherapy, targeted therapy and anti-hormonal therapy of elderly patients with breast cancer – data from the SENORA project.

Zahn, M.-O., Tesch, H., Köhler, A., Fietz, T., Münz, M., Kruggel, L., Jänicke, M., Marscher, N., 2014.

Oncol Res Treat 37 (suppl 5)(V374), 112. doi:10.1159/000368945

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2014

No impact of first-line systemic therapy on quality of life of patients with metastatic breast cancer? Data from the MaLife-project.

Marschner, N., Tesch, H., Karcher, A., Ammon, A., Nusch, A., Boller, E., Spring, L., Jänicke, M., 2014.

Oncol Res Treat 37 (suppl 5)(V371), 111. doi:10.1159/000368945

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2014

Long-term side effects of curative treatment for breast cancer – data from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V370), 110. doi:10.1159/000368945

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2014

Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC).

Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013.

Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

CARIN
2013

Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

van de Water, W., Seynaeve, C., Bastiaannet, E., Markopoulos, C., Jones, S.E., Rea, D., Hasenburg, A., Putter, H., Hille, E.T.M., Paridaens, R., de Craen, A.J.M., Westendorp, R.G.J., van de Velde, C.J.H., Liefers, G.-J., 2013.

Oncologist 18, 8–13. doi:10.1634/theoncologist.2012-0315

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Oncologist

TEAM
2013

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com